The present embodiments relate generally to medical devices, and more particularly to apparatus and methods for delivering therapeutic agents to a target site.
There are several instances in which it may become desirable to introduce therapeutic agents into the human or animal body. For example, therapeutic drugs or bioactive materials may be introduced to achieve a biological effect. The biological effect may include an array of targeted results, such as inducing hemostasis, sealing perforations, reducing restenosis likelihood, or treating cancerous tumors or other diseases.
Many of such therapeutic agents are injected using an intravenous (IV) technique and via oral medicine. While such techniques permit the general introduction of medicine, in many instances it may be desirable to provide localized or targeted delivery of therapeutic agents, which may allow for the guided and precise delivery of agents to selected target sites. For example, localized delivery of therapeutic agents to a tumor may reduce the exposure of the therapeutic agents to normal, healthy tissues, which may reduce potentially harmful side effects.
Localized delivery of therapeutic agents has been performed using catheters and similar introducer devices. By way of example, a catheter may be advanced towards a target site within the patient, and then the therapeutic agent may be injected through a lumen of the catheter to the target site. Typically, a syringe or similar device may be used to inject the therapeutic agent into the lumen of the catheter. However, such a delivery technique may result in a relatively weak stream of the injected therapeutic agent.
Moreover, it may be difficult or impossible to deliver therapeutic agents in a targeted manner in certain forms, such as a powder form, to a desired site. For example, if a therapeutic powder is held within a syringe or other container, it may not be easily delivered through a catheter to a target site in a localized manner that may also reduce potentially harmful side effects.
The present embodiments provide apparatus and methods suitable for containing a therapeutic agent and delivering it to a target site. The apparatus generally comprises at least one container for holding a therapeutic agent, and a pressure source for facilitating delivery of the therapeutic agent.
In one embodiment, the pressure source may be placed in selective fluid communication with a proximal end of the container. Fluid from the pressure source may flow through at least a portion of the container to urge the therapeutic agent through a distal end of the container and towards the target site. The pressure source may comprise a compressed gas dispenser.
At least one tube member, such as a catheter, may be used to facilitate delivery of the therapeutic agent from the container to the target site. The catheter may be placed in fluid communication with the distal region of the container. In use, fluid from the pressure source urges the therapeutic agent through the container, through the catheter, and then distally towards the target site.
The container has a proximal end and a distal end that may be closed by pregnable sealing members. The container is designed to control the flow of therapeutic agent through the tube member in order to provide a consistent, uniform amount with each use. In one embodiment, the container comprises a tube member held preferably at about the radial center of the container near the distal end. A plug holds the tube member in place and has an outer diameter that is approximately equal to the interior of the container, so that it prevents any therapeutic agent that does not pass through the tube member from exiting the distal end of the container.
In one embodiment, a flow obstruction member is placed preferably at about the radial center of the container and proximally adjacent to the tube member. A support member, comprised of a wire or other suitable material, is coupled to the flow obstruction member and is held in place by a support structure. The support structure and support member, in combination, maintain the flow obstruction member in place. When fluid from the pressure source enters the container, it forces therapeutic agent to travel around the flow obstruction member so that a certain amount of therapeutic agent is directed through the tube member to be delivered to the target site.
In another embodiment, the container does not contain a tube member, but instead comprises flow obstruction members placed along the interior of the container that are designed to promote the delivery of a consistent, uniform amount of therapeutic agent with each use.
In any of the embodiments, switches may be placed at the proximal and distal ends of the container in order to control when fluid from the pressure source may enter the container and push the therapeutic agent into the catheter. If pregnable seals are used, the switches may also be used to perforate the seals surrounding the container. Additionally, a valve may be placed in fluid communication between the pressure source and the container so that the fluid from the pressure source bypasses the container entirely and then enters the catheter in order to clear the catheter of any excess therapeutic agent.
Other systems, methods, features and advantages of the invention will be, or will become, apparent to one with skill in the art upon examination of the following figures and detailed description. It is intended that all such additional systems, methods, features and advantages be within the scope of the invention, and be encompassed by the following claims.
The invention can be better understood with reference to the following drawings and description. The components in the figures are not necessarily to scale, emphasis instead being placed upon illustrating the principles of the invention. Moreover, in the figures, like referenced numerals designate corresponding parts throughout the different views.
In the present application, the term “proximal” refers to a direction that is generally towards a physician during a medical procedure, while the term “distal” refers to a direction that is generally towards a target site within a patient's anatomy during a medical procedure.
Referring now to
The pressure source 70 may comprise one or more components capable of producing or furnishing a fluid having a desired pressure. In one embodiment, the pressure source 70 may comprise a pressurized fluid cartridge 72 comprised of a selected gas or liquid—or a combination of gas and liquid—such as carbon dioxide, nitrogen, or any other suitable gas or liquid that may be compatible with the human body. The pressurized fluid cartridge 72 may contain the gas or liquid at a relatively high, first predetermined pressure, for example, around 1,800 psi inside of the cartridge. The fluid may flow from the pressurized fluid cartridge 72 through a pressure regulator, such as regulator valve 73 having a pressure outlet, which may reduce the pressure to a lower, second predetermined pressure or to achieve a set flow rate. Solely by way of example, the second predetermined pressure may be in the range of about 30 to about 80 psi, although any suitable pressure may be provided for the purposes described below. Therapeutic agent is disposed within the container 18. The pressure source 70 propels fluid from the pressurized fluid cartridge 72 distally through the container 18 and through the catheter 46. In other embodiments, the pressure source 70 may comprise a compressible ball or a syringe. An inner diameter d1 of the catheter 46 may vary, but a preferred inner diameter ranges from about 0.085 inches to about 0.100 inches.
Referring now to
The container 18 further comprises a tube member 22 that has a distal end 37 that is located near a distal end 30 of the container 18. A diameter of the tube member 22 may vary, but a preferred range in outer diameter is about 0.23 inches to about 0.27 inches and a preferred inner diameter d2 ranges from about 0.19 to about 0.22 inches. The tube member 22 extends to a position proximate to the flow obstruction member 26. While a distance r1 from the tube member 22 to the flow obstruction member 26 may vary, a preferred range of distance r1 is about 0.25 mm to about 0.35 mm. The distal end 37 of the tube member 22 may extend distally up to or beyond the distal end of the container 18. The tube member 22 preferably does not directly abut or touch the flow obstruction member 26, and is held preferably at about the radial center of the container 18 by a plug 20. In this embodiment, the plug 20 is disc-shaped. An outer diameter of the plug 20 is equal to or slightly less than a diameter of an interior surface 19 of the container 18 so as to form a seal between the plug 20 and the interior surface 19 to prevent any therapeutic agent from reaching the distal end 30 of the container 18 without passing through the tube member 22. The container 18 may also be sealed by sealing members 25, with one at the distal end 30 as depicted in
The container 18 may comprise any suitable size and shape for holding a therapeutic agent 33. In alternative embodiments wherein the container is not cylindrical in shape, the support structure 24 and the plug 20 will be made out of shapes necessary to prevent therapeutic agent from reaching the distal end 30 through routes other than through the tube member 22.
The flow obstruction member 26 may comprise any suitable shape for controlling the rate of flow of the therapeutic agent into the tube member 22. When fluid from the pressure source 70 enters the container 18 through an inlet port 35, the fluid travels around the flow obstruction member 26 and tends to travel along the surface of the flow obstruction member 26. As the fluid continues past the tube member 22, the fluid creates a pressure differential wherein the resulting lower pressure within the tube member 22 draws therapeutic agent 33 into the tube member 22. Without the flow obstruction member 26, the therapeutic agent 33 would flow in a haphazard, turbulent manner toward the distal end of the container 18, and a non-uniform amount of therapeutic agent 33 would pass through the tube member 22. As depicted in
Depicted in
The container 18 also may comprise measurement indicia, which allow a user to determine a quantity of the therapeutic agent 33 that is held within the container 18, as explained in commonly assigned pending U.S. application Ser. No. 12/435,574 (“the '574 application”), filed May 5, 2009, which is hereby incorporated by reference in its entirety. Optionally, a valve member may be disposed between the reservoir of the container 18 and the catheter 46 to selectively permit and inhibit fluid communication between the container 18 and the catheter 46, as further described in the '574 application.
Referring now to FIGS. 1 and 10-12, an actuator, such as a button, may be used to selectively actuate the pressure source 70. The pressurized fluid may flow from the pressurized fluid cartridge 72, and subsequently through the regulator valve 73 using an adapter, as explained in the '574 application. The adapter may be configured to be sealingly coupled to the pressurized fluid cartridge 72, as further explained in the '574 application. Further, the adapter may be coupled to tubing, which allows the pressurized fluid to flow into the regulator valve. A proximal end of a different tubing may be adapted to be coupled to the regulator valve 73, as shown in the '574 application, thereby enabling the pressurized fluid to flow through the regulator valve 73 and into the tubing at the lower, second predetermined pressure.
The pressure source 70 optionally may comprise one or more commercially available components. Solely by way of example, the pressurized fluid cartridge 72 may comprise a disposable carbon dioxide cartridge, such as the Visage® commercial dispenser manufactured by Helen of Troy®, El Paso, Tex. The pressure source 70 therefore may comprise original or retrofitted components capable of providing a fluid or gas into the tubing at a desired regulated pressure.
One or more catheters may be used to deliver the therapeutic agent 33 to a target site. Referring to
Referring to
In addition, end-viewing and side-viewing endoscopes may be used, as described in the '574 application. The endoscopes may be advanced through a bodily lumen such as the alimentary canal to a position proximate the target location. The catheter 46 then may be advanced through the working lumen of the endoscope. If the needle 95 is employed, a sharpened tip 96 of the needle 95 may extend distal to the endoscope, and may be used to puncture through an organ or a gastrointestinal wall or tissue. At this time, the therapeutic agent 33 may be delivered through the catheter 46, then through a bore 97 in the needle 95, in the manner described above and in the '574 application.
In operation, the apparatus of FIGS. 1 and 10-13 may be used to deliver the therapeutic agent 33 to a target site within a patient's body. In a first step, the distal end of the catheter 46 may be positioned in relatively close proximity to the target site. The catheter 46 may be advanced to the target site using an open technique, a laparoscopic technique, an intraluminal technique, using a gastroenterology technique through the mouth, colon, or using any other suitable technique.
The catheter 46 may comprise one or more markers (not shown), which may be disposed near the distal end of the catheter 46. The markers may be configured to be visualized under fluoroscopy or other imaging techniques to facilitate location of the distal end of the catheter 46. If the needle 95 is integral to the catheter 46, the needle 95 also may be visualized using the imaging techniques, thereby allowing placement of the distal end of the catheter 46 in close proximity to the target site. If desired, the catheter 46 may be advanced through a working lumen of an endoscope, as explained in further detail in the '574 application.
When the catheter 46 is positioned at the desired location, the pressure source 70 may be actuated. As noted above, a button or other actuator may be coupled to the pressurized fluid cartridge 72 to release a relatively high pressure fluid. As noted above, the pressurized fluid may flow through a regulator valve 73 and through the container 18 at a desired pressure and rate. For example, the regulator valve may automatically set the pressure for fluid flow, or alternatively, a control mechanism coupled to the pressurized fluid cartridge and/or the regulator valve may be activated by a user to set the desired pressure for fluid flow into the container 18. Such a control mechanism also may be used to variably permit fluid flow into the container 18, e.g., fluid from the pressurized fluid cartridge 72 may flow into the container 18 at a desired time interval, for example, a predetermined quantity of fluid per second. Moreover, the control mechanism may be pre-programmed to deliver a predetermined amount of the therapeutic agent, depending on the type, viscosity, and other properties of the agent. Empirical information, such as a table of pressure, time and delivered quantity, may be stored and used for the different agents or procedures.
Fluid from the pressure source 70 flows through the proximal end 32 of the container 18, around the obstruction flow member 26 and into the tube member 22, through the distal end 30 and then through a lumen of the catheter 46. Fluid may exit the distal end of the catheter 46, for example, through a bore formed in the needle 95. In addition, the orientation of container 18 in regards to the pressure source 70 may vary. For example, the container 18 may be aligned parallel to the pressure source 70 as described in U.S. Application No. 61/182,463 filed May 29, 2009, the disclosure of which is incorporated herein by reference in its entirety.
As noted above, a valve member optionally may be disposed between the reservoir of the container 18 and a connecting member, as shown in the '574 application. A user may selectively actuate the valve member to periodically permit and inhibit fluid communication between the container and the connecting member. The valve member also may serve as a “shut-off” safety mechanism to inhibit withdrawal of the therapeutic agent from the reservoir, even when pressurized fluid is flowing through the connecting member.
As noted above and depicted in the '574 application, a control mechanism coupled to the pressure source 70 may variably permit fluid flow into the tubing from the pressurized fluid cartridge 72 at a desired time interval, for example, a predetermined quantity of fluid per second. In this manner, pressurized fluid may flow through the catheter periodically, and the therapeutic agent 33 may be delivered to a target site at a predetermined interval or otherwise periodic basis.
The apparatus may be used to deliver the therapeutic agent 33 in a wide range of procedures and the therapeutic agent 33 may be chosen to perform a desired function upon ejection from the distal end of the catheter 46. Solely by way of example, and without limitation, the provision of the therapeutic agent 33 may be used for providing hemostasis; closing perforations; performing lithotripsy; delivering drugs; treating tumors and cancers; and treating renal dialysis fistulae stenosis, vascular graft stenosis, and the like. The size of the catheter 46 used to deliver the therapeutic agent 33 may vary depending upon the procedure for which it is being used; for example, a short catheter may be used for external use on irregularly shaped lacerations. The size of the therapeutic agent 33 may also vary, although a preferred embodiment of a therapeutic agent 33 for hemostasis has a 325 mesh size.
The therapeutic agent 33 can be delivered during procedures such as coronary artery angioplasty, renal artery angioplasty and carotid artery surgery, or may be used generally for treating various other cardiovascular, respiratory, gastroenterology or other conditions. The above-mentioned systems also may be used in transvaginal, umbilical, nasal, and bronchial/lung related applications.
For example, if used for purposes of hemostasis, thrombin, epinephrine, or a sclerosant may be provided to reduce localized bleeding. Similarly, if used for closing a perforation, a fibrin sealant may be delivered to a localized lesion. In addition to the hemostatic properties of the therapeutic agent 33, it should be noted that the relatively high pressure of the fluid and therapeutic agent, by itself, may act as a mechanical tamponade by providing a compressive force, thereby reducing the time needed to achieve hemostasis.
The therapeutic agent 33 may be selected to perform one or more desired biological functions, for example, promoting the ingrowth of tissue from the interior wall of a body vessel, or alternatively, to mitigate or prevent undesired conditions in the vessel wall, such as restenosis. Many other types of therapeutic agents 33 may be used in conjunction with the apparatus.
The therapeutic agent 33 may be delivered in any suitable form. For example, the therapeutic agent 33 may comprise a powder, liquid, gel, aerosol, or other substance. Advantageously, the pressure source 70 may facilitate delivery of the therapeutic agent 33 in any one of these forms.
The therapeutic agent 33 employed also may comprise an antithrombogenic bioactive agent, e.g., any bioactive agent that inhibits or prevents thrombus formation within a body vessel. Types of antithrombotic bioactive agents include anticoagulants, antiplatelets, and fibrinolytics. Anticoagulants are bioactive materials which act on any of the factors, cofactors, activated factors, or activated cofactors in the biochemical cascade and inhibit the synthesis of fibrin. Antiplatelet bioactive agents inhibit the adhesion, activation, and aggregation of platelets, which are key components of thrombi and play an important role in thrombosis. Fibrinolytic bioactive agents enhance the fibrinolytic cascade or otherwise aid in dissolution of a thrombus. Examples of antithrombotics include but are not limited to anticoagulants such as thrombin, Factor Xa, Factor VIIa and tissue factor inhibitors; antiplatelets such as glycoprotein IIb/IIIa, thromboxane A2, ADP-induced glycoprotein IIb/IIIa, and phosphodiesterase inhibitors; and fibrinolytics such as plasminogen activators, thrombin activatable fibrinolysis inhibitor (TAFI) inhibitors, and other enzymes which cleave fibrin.
Additionally, or alternatively, the therapeutic agent 33 may include thrombolytic agents used to dissolve blood clots that may adversely affect blood flow in body vessels. A thrombolytic agent is any therapeutic agent that either digests fibrin fibers directly or activates the natural mechanisms for doing so. Examples of commercial thrombolytics, with the corresponding active agent in parenthesis, include, but are not limited to, Abbokinase (urokinase), Abbokinase Open-Cath (urokinase), Activase (alteplase, recombinant), Eminase (anitstreplase), Retavase (reteplase, recombinant), and Streptase (streptokinase). Other commonly used names are anisoylated plasminogen-streptokinase activator complex; APSAC; tissue-type plasminogen activator (recombinant); t-PA; rt-PA. While a few exemplary therapeutic agents 33 have been listed, it will be apparent that numerous other suitable therapeutic agents may be used in conjunction with the apparatus and delivered through the catheter 46.
Advantageously, the apparatus permits localized delivery of a desired quantity of the therapeutic agent 33 at a desired pressure via the pressure source 70. Since the distal end of the catheter 46 may be placed in relatively close proximity to a target site, the apparatus provides significant advantages over therapeutic agents delivered orally or through an IV system and may reduce accumulation of the therapeutic agent 33 in healthy tissues, thereby reducing side effects. Moreover, the delivery of the therapeutic agent 33 to the target site is performed in a relatively fast manner due to the relatively high pressure of the fluid, thereby providing a prompt delivery to the target site compared to previous devices.
Further, if the optional needle 95 is employed, the apparatus advantageously may be used both to perforate tissue at or near a target site, and then deliver the therapeutic agent 33 at a desired pressure in the manner described above. For example, the needle 95 may comprise an endoscopic ultrasound (EUS) needle. Accordingly, in one exemplary technique, a sharpened tip of the needle 95 may be capable of puncturing through an organ or a gastrointestinal wall or tissue, so that the therapeutic agent 33 may be delivered at a predetermined pressure in various bodily locations that may be otherwise difficult to access. One or more delivery vehicles, such as an endoscope or sheath, may be employed to deliver the catheter 46 to a target site, particularly if the distal end of the catheter 46 comprises the optional needle 95.
Referring now to
In the embodiment depicted in
Referring again to
Referring now to
In the embodiment of
Referring now to
While various embodiments of the invention have been described, the invention is not to be restricted except in light of the attached claims and their equivalents. Moreover, the advantages described herein are not necessarily the only advantages of the invention and it is not necessarily expected that every embodiment of the invention will achieve all of the advantages described.
This application claims the benefit of U.S. Provisional Application No. 61/140,379 filed on Dec. 23, 2008, entitled “APPARATUS AND METHODS FOR CONTAINING AND DELIVERING THERAPEUTIC AGENTS,” the entire contents of which are incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
39678 | Russell | Aug 1863 | A |
170182 | Molesworth | Nov 1875 | A |
442785 | Schoettl | Dec 1890 | A |
460458 | Bates | Sep 1891 | A |
471865 | Howard | Mar 1892 | A |
533489 | Ogram | Feb 1895 | A |
566411 | Schoene | Aug 1896 | A |
576437 | Elliott | Feb 1897 | A |
693587 | Campbell | Feb 1902 | A |
775985 | McKain | Nov 1904 | A |
881238 | Hasbrouck | Mar 1908 | A |
904149 | Rachmann | Nov 1908 | A |
938648 | DeVilbiss | Nov 1909 | A |
1022601 | Rumberg et al. | Apr 1912 | A |
1114114 | Cochenour | Oct 1914 | A |
1145520 | Smith | Jul 1915 | A |
1261503 | Figgis | Apr 1918 | A |
1357452 | Hall | Nov 1920 | A |
1466119 | Claflin | Aug 1923 | A |
1521396 | Scott | Dec 1924 | A |
1685280 | Findley | Sep 1928 | A |
1934793 | Crain et al. | Nov 1933 | A |
2004402 | Conklin | Jun 1935 | A |
2151418 | Bolte | Mar 1939 | A |
2223611 | Gross | Dec 1940 | A |
2307986 | Bolte et al. | Jan 1943 | A |
2390313 | Macgill | Dec 1945 | A |
2507702 | Fields | May 1950 | A |
2519555 | Fields | Aug 1950 | A |
2609155 | Fosnaugh | Sep 1952 | A |
2632444 | Kas | Mar 1953 | A |
2850013 | Cordis | Sep 1958 | A |
2934314 | Chambers et al. | Apr 1960 | A |
2956579 | Moore et al. | Oct 1960 | A |
3016895 | Sein et al. | Jan 1962 | A |
3050261 | Littlefield | Aug 1962 | A |
3506008 | Huck | Apr 1970 | A |
3540444 | Moreland | Nov 1970 | A |
3572335 | Robinson | Mar 1971 | A |
3589363 | Banko et al. | Jun 1971 | A |
3599866 | Bolton | Aug 1971 | A |
3632046 | Hengesbach | Jan 1972 | A |
3647143 | Gauthier et al. | Mar 1972 | A |
3649299 | Sholl | Mar 1972 | A |
3667465 | Voss | Jun 1972 | A |
3710400 | Sparks | Jan 1973 | A |
3742955 | Battista et al. | Jul 1973 | A |
3744493 | Booher et al. | Jul 1973 | A |
3762410 | Bindel | Oct 1973 | A |
3788315 | Laurens | Jan 1974 | A |
3815595 | Bar | Jun 1974 | A |
3900022 | Widran | Aug 1975 | A |
3916896 | Ballard | Nov 1975 | A |
4017007 | Riccio | Apr 1977 | A |
4040420 | Speer | Aug 1977 | A |
4174811 | Binder et al. | Nov 1979 | A |
4184258 | Barrington et al. | Jan 1980 | A |
4204539 | Van Brugge | May 1980 | A |
4204645 | Hopp | May 1980 | A |
4210140 | James et al. | Jul 1980 | A |
4359049 | Redl et al. | Nov 1982 | A |
4423727 | Widran et al. | Jan 1984 | A |
4427650 | Stroetmann | Jan 1984 | A |
4516442 | Davis | May 1985 | A |
4534345 | Wetterlin | Aug 1985 | A |
4539716 | Bell | Sep 1985 | A |
4552556 | Urquhart et al. | Nov 1985 | A |
4578067 | Cruz, Jr. | Mar 1986 | A |
4606501 | Bate et al. | Aug 1986 | A |
4620847 | Shishov et al. | Nov 1986 | A |
4631055 | Redl et al. | Dec 1986 | A |
4637816 | Mann | Jan 1987 | A |
H257 | Barditch et al. | Apr 1987 | H |
4655211 | Sakamoto et al. | Apr 1987 | A |
4735616 | Eibl et al. | Apr 1988 | A |
4738658 | Magro et al. | Apr 1988 | A |
4738740 | Pinchuk | Apr 1988 | A |
4752466 | Saferstein et al. | Jun 1988 | A |
4790819 | Li et al. | Dec 1988 | A |
4798606 | Pinchuk | Jan 1989 | A |
4803977 | Kremer, Jr. | Feb 1989 | A |
4846405 | Zimmermann | Jul 1989 | A |
D303139 | Morgan | Aug 1989 | S |
4872450 | Austad | Oct 1989 | A |
4874368 | Miller et al. | Oct 1989 | A |
4890612 | Kensey | Jan 1990 | A |
4900303 | Lemelson | Feb 1990 | A |
4902278 | Maget et al. | Feb 1990 | A |
4902281 | Avoy | Feb 1990 | A |
4927410 | Kovacs | May 1990 | A |
4929246 | Sinofsky | May 1990 | A |
4941874 | Sandow et al. | Jul 1990 | A |
4941880 | Burns | Jul 1990 | A |
4945050 | Sanford et al. | Jul 1990 | A |
4946870 | Partain, III. et al. | Aug 1990 | A |
4950234 | Fujioka et al. | Aug 1990 | A |
4969874 | Michel et al. | Nov 1990 | A |
4978336 | Capozzi et al. | Dec 1990 | A |
4994028 | Leonard et al. | Feb 1991 | A |
5009637 | Newman et al. | Apr 1991 | A |
5015580 | Christou et al. | May 1991 | A |
5021059 | Kensey et al. | Jun 1991 | A |
5053000 | Booth et al. | Oct 1991 | A |
5059187 | Sperry et al. | Oct 1991 | A |
5061180 | Wiele | Oct 1991 | A |
5063025 | Ito | Nov 1991 | A |
5064413 | McKinnon et al. | Nov 1991 | A |
5106370 | Stewart | Apr 1992 | A |
5116315 | Capozzi et al. | May 1992 | A |
5120657 | McCabe et al. | Jun 1992 | A |
5129825 | Discko, Jr. | Jul 1992 | A |
5129882 | Weldon et al. | Jul 1992 | A |
5133701 | Han | Jul 1992 | A |
5141515 | Eberbach | Aug 1992 | A |
5147292 | Kullas et al. | Sep 1992 | A |
5149655 | McCabe et al. | Sep 1992 | A |
5165604 | Copp, Jr. | Nov 1992 | A |
5176642 | Clement | Jan 1993 | A |
5179022 | Sanford et al. | Jan 1993 | A |
D333000 | Good et al. | Feb 1993 | S |
5204253 | Sanford et al. | Apr 1993 | A |
5219328 | Morse et al. | Jun 1993 | A |
5226567 | Sansalone | Jul 1993 | A |
5226877 | Epstein | Jul 1993 | A |
RE34365 | Theeuwes | Aug 1993 | E |
5273531 | Knoepfler | Dec 1993 | A |
5292309 | Van Tassel et al. | Mar 1994 | A |
5310407 | Casale | May 1994 | A |
5312333 | Churinetz et al. | May 1994 | A |
5328459 | Laghi | Jul 1994 | A |
5330426 | Kriesel et al. | Jul 1994 | A |
5391183 | Janzen et al. | Feb 1995 | A |
5392992 | Farnsteiner et al. | Feb 1995 | A |
5395326 | Haber et al. | Mar 1995 | A |
5405607 | Epstein | Apr 1995 | A |
5415631 | Churinetz et al. | May 1995 | A |
5429278 | Sansalone | Jul 1995 | A |
5445612 | Terakura et al. | Aug 1995 | A |
5447499 | Allaire et al. | Sep 1995 | A |
5469994 | Reh et al. | Nov 1995 | A |
5470311 | Setterstrom et al. | Nov 1995 | A |
5484403 | Yoakum et al. | Jan 1996 | A |
5503623 | Tilton, Jr. | Apr 1996 | A |
5520658 | Holm | May 1996 | A |
5538162 | Reh et al. | Jul 1996 | A |
5553741 | Sancoff et al. | Sep 1996 | A |
5558646 | Roche | Sep 1996 | A |
5582596 | Fukunaga et al. | Dec 1996 | A |
5584807 | McCabe | Dec 1996 | A |
5584815 | Pawelka et al. | Dec 1996 | A |
5601603 | Illi | Feb 1997 | A |
5605541 | Holm | Feb 1997 | A |
5612050 | Rowe et al. | Mar 1997 | A |
5665067 | Linder et al. | Sep 1997 | A |
5697947 | Wolf et al. | Dec 1997 | A |
5707402 | Heim | Jan 1998 | A |
5749968 | Melanson et al. | May 1998 | A |
5759171 | Coelho et al. | Jun 1998 | A |
5788625 | Plouhar et al. | Aug 1998 | A |
5865796 | McCabe | Feb 1999 | A |
5873530 | Chizinsky | Feb 1999 | A |
5902228 | Schulsinger et al. | May 1999 | A |
5919184 | Tilton, Jr. | Jul 1999 | A |
5951531 | Ferdman et al. | Sep 1999 | A |
6007515 | Epstein et al. | Dec 1999 | A |
6013050 | Bellhouse et al. | Jan 2000 | A |
6021776 | Allred et al. | Feb 2000 | A |
6027471 | Fallon et al. | Feb 2000 | A |
6059749 | Marx | May 2000 | A |
6077217 | Love et al. | Jun 2000 | A |
6117150 | Pingleton et al. | Sep 2000 | A |
6165201 | Sawhney et al. | Dec 2000 | A |
6368300 | Fallon et al. | Apr 2002 | B1 |
6394975 | Epstein | May 2002 | B1 |
6428505 | Taylor | Aug 2002 | B1 |
6454786 | Holm et al. | Sep 2002 | B1 |
6461325 | Delmotte et al. | Oct 2002 | B1 |
6461361 | Epstein | Oct 2002 | B1 |
6478754 | Babaev | Nov 2002 | B1 |
6537246 | Unger et al. | Mar 2003 | B1 |
6554792 | Hughes | Apr 2003 | B2 |
6610026 | Cragg et al. | Aug 2003 | B2 |
6641800 | Mistry et al. | Nov 2003 | B1 |
6689108 | Lavi et al. | Feb 2004 | B2 |
6716190 | Glines et al. | Apr 2004 | B1 |
6723067 | Nielson | Apr 2004 | B2 |
6811550 | Holland et al. | Nov 2004 | B2 |
6843388 | Hollars | Jan 2005 | B1 |
6863660 | Marx | Mar 2005 | B2 |
6905475 | Hauschild et al. | Jun 2005 | B2 |
6939324 | Gonnelli et al. | Sep 2005 | B2 |
7101862 | Cochrum et al. | Sep 2006 | B2 |
7156880 | Evans et al. | Jan 2007 | B2 |
7182748 | Potter et al. | Feb 2007 | B1 |
7291133 | Kindler et al. | Nov 2007 | B1 |
7334598 | Hollars | Feb 2008 | B1 |
7534449 | Saltzman et al. | May 2009 | B2 |
7544177 | Gertner | Jun 2009 | B2 |
7632245 | Cowan et al. | Dec 2009 | B1 |
7673783 | Morgan et al. | Mar 2010 | B2 |
7691244 | Levitan et al. | Apr 2010 | B2 |
7744526 | McAllister et al. | Jun 2010 | B2 |
7776822 | Terman | Aug 2010 | B2 |
7824373 | Kim | Nov 2010 | B2 |
7857167 | Hollars | Dec 2010 | B1 |
20010056256 | Hughes et al. | Dec 2001 | A1 |
20020165483 | Miller et al. | Nov 2002 | A1 |
20020169416 | Gonnelli | Nov 2002 | A1 |
20030023202 | Nielson | Jan 2003 | A1 |
20030108511 | Sawhney | Jun 2003 | A1 |
20030170250 | Ezrin et al. | Sep 2003 | A1 |
20030181917 | Gertner | Sep 2003 | A1 |
20030216695 | Yang | Nov 2003 | A1 |
20040059283 | Kirwan et al. | Mar 2004 | A1 |
20050070848 | Kim et al. | Mar 2005 | A1 |
20060002852 | Saltzman et al. | Jan 2006 | A1 |
20060052295 | Terman | Mar 2006 | A1 |
20060286664 | McAllister et al. | Dec 2006 | A1 |
20070088317 | Hyde | Apr 2007 | A1 |
20070240989 | Levitan et al. | Oct 2007 | A1 |
20070241119 | Durkin et al. | Oct 2007 | A1 |
20080027272 | Kadykowski | Jan 2008 | A1 |
20080132891 | Nobis et al. | Jun 2008 | A1 |
20080287911 | El-Nounou et al. | Nov 2008 | A1 |
20090234374 | Gabel et al. | Sep 2009 | A1 |
20090234380 | Gabel et al. | Sep 2009 | A1 |
20090248056 | Gabel et al. | Oct 2009 | A1 |
20100137796 | Perry et al. | Jun 2010 | A1 |
Number | Date | Country |
---|---|---|
15244 | Sep 1897 | CH |
257250 | Sep 1948 | CH |
3024749 | Feb 1982 | DE |
3108918 | Sep 1982 | DE |
3613762 | Nov 1987 | DE |
0 308 269 | Sep 1988 | EP |
0 738 498 | Apr 1996 | EP |
10563 | Jan 1896 | GB |
1 254 534 | Nov 1971 | GB |
4-22109 | Apr 1992 | JP |
978999 | Dec 1982 | SU |
WO 8203545 | Oct 1982 | WO |
WO 8502346 | Jun 1985 | WO |
WO 9220312 | Nov 1992 | WO |
WO 9428798 | Dec 1994 | WO |
WO 9625190 | Aug 1996 | WO |
WO 9637245 | Nov 1996 | WO |
WO 9640327 | Dec 1996 | WO |
WO 9720585 | Jun 1997 | WO |
WO 02053014 | Jul 2002 | WO |
WO 2004073863 | Sep 2004 | WO |
WO 2005100980 | Oct 2005 | WO |
WO 2008008845 | Jan 2008 | WO |
Entry |
---|
International Search Report and Written Opinion for PCT/US2010/036381, mailed Aug. 20, 2010, 16 pgs. |
International Preliminary Report on Patentability for PCT/US2009/042781, mailed Nov. 18, 2010, 11 pgs. |
International Search Report completed Sep. 22, 2009 for PCT/US2009/042781, 7 pgs. |
Alto Shooter Catalog, Kaigen, English and Japanese, Jun. 1994, 8 pgs. |
Decker, “An Efficient Method for The Application of Avitene® Hemostatic Agent”, Surgery, Gynecology & Obstetrics, 1991, vol. 172, No. 6, 2 pgs. |
Endo-Avitene™ brochure, Med Chem Products, Inc., date unknown, 4 pgs. |
Fagelman, et al., “A Simple Method for Application of Microfibrillar Collagen,” Surgery. Gynecology & Obstetrics, Jun. 1980, vol. 150, No. 6, 3 pgs. |
Hoshino et al., “Trans-endoscopic Drug Propulsion Therapy”, Digestive Endoscopy, 1993 vol. 5, 6 pgs. |
The Surgical Armamentarium, Copyright 1973, V. Mueller, 3 pgs. |
Response to Office Action dated Nov. 3, 2010 for U.S. Appl. No. 12/435,574, 10 pgs. |
Final Office Action dated Feb. 17, 2011 for U.S. Appl. No. 12/435,574, 8 pgs. |
Non-Final Office Action dated Apr. 14, 2011 for U.S. Appl. No. 12/787,796, 9 pgs. |
Office Action dated Aug. 4, 2010 pertaining to U.S. Appl. No. 12/435,574 which is incorporated by reference in this application. |
Response to Office Action for U.S. Appl. No. 12/787,796, filed Jul. 14, 2011, 11 pgs. |
Notice of Allowance for U.S. Appl. No. 12/787,796 dated Oct. 18, 2011, 10 pgs. |
Final Office Action for U.S. Appl. No. 12/435,574 mailed Feb. 17, 2011, 8 pgs. |
Response to Final Office Action for U.S. Appl. No. 12/435,574, filed May 13, 2011, 11 pgs. |
Examiner Interview Summary for U.S. Appl. No. 12/435,574 dated Jun. 10, 2011, 3 pgs. |
Notice of Appeal for U.S. Appl. No. 12/435,574, filed Aug. 17, 2011, 1 pg. |
Office Action for U.S. Appl. No. 12/435,574 mailed Aug. 22, 2011, 9 pgs. |
Response to Office Action for U.S. Appl. No. 12/435,574, filed Nov. 22, 2011, 10 pgs. |
Office Action for U.S. Appl. No. 12/435,574 mailed Mar. 30, 2012, 9 pgs. |
Response to Office Action for U.S. Appl. No. 12/435,574, filed Aug. 30, 2012, 11 pgs. |
International Search Report mailed Apr. 14, 2010 for PCT/US2009/067076, 8 pgs. |
Hoshino, “Transendoscopic Projectile Drug Delivery”, Gastroenterologia Japonica, vol. 25, No. 5, Jun. 15, 1990, 1 page. |
Park et al., “A randomized comparison of a new flexible bipolar hemostasis forceps designed principally for NOTES versus a conventional surgical laparoscopic bipolar forceps for intra-abdominal vessel sealing in a porcine model”, Gastrointestinal Endoscopy 2010, vol. 71, No. 4, pp. 835-841. |
Fritscher-Ravens et al., “Beyond NOTES: randomized controlled study of different methods of flexible endoscopic hemostasis of artifically induced hemorrhage, via NOTES access to the peritoneal cavity”, Endoscopy 2009, vol. 41, pp. 29-35. |
Number | Date | Country | |
---|---|---|---|
20100160897 A1 | Jun 2010 | US |
Number | Date | Country | |
---|---|---|---|
61140379 | Dec 2008 | US |